A study of novel anti-cancer agents in patients with previously untreated NSCLC - MAGELLAN

Study identifier:D933IC00001

ClinicalTrials.gov identifier:NCT03819465

EudraCT identifier:2018-001748-74

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)

Medical condition

Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase

Phase 1

Healthy volunteers

No

Study drug

Durvalumab, Durvalumab, Durvalumab, Durvalumab, Durvalumab, Durvalumab, Danvatirsen, Danvatirsen, Oleclumab, Oleclumab, MEDI5752, MEDI5752, Pemetrexed, Pemetrexed, Pemetrexed, Pemetrexed, Carboplatin, Carboplatin, Carboplatin, Carboplatin, Gemcitabine, Gemcitabine, Gemcitabine, Cisplatin, Cisplatin, Cisplatin, Cisplatin, Nab-paclitaxel, Nab-paclitaxel, Nab-paclitaxel, AZD2936, AZD2936

Sex

All

Actual enrollment

175

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 27 Dec 2018
Estimated Primary Completion Date: 23 May 2023
Estimated Study Completion Date: 23 May 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 May 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria